New Mechanism for Gene Therapy Brain Delivery
Researchers have developed a new bispecific antibody delivery system that targets both TfR1 and CD98hc receptors to improve drug delivery across the blood-brain barrier. This method enhances the transport of RNA-based therapies, offering a potential breakthrough for treating neurological disorders.
Why it matters
Overcoming the blood-brain barrier is a primary challenge in developing effective treatments for brain-related diseases.
MAJOR steps forward in addressing drug delivery gap for neurological disorders in research published using antibody-based Brainshuttle™ technology. Promising therapeutic modalities such as RNA-based antisense oligonucleotides (ASOs) can precisely regulate disease-related genes but face limited clinical utility as they’re unable to cross the blood brain barrier (BBB).
The content is a technical summary of scientific research findings with no political or social bias.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in